RU2019112526A - Pharmaceutical composition of Galleria mellonella larvae and method for its production - Google Patents

Pharmaceutical composition of Galleria mellonella larvae and method for its production Download PDF

Info

Publication number
RU2019112526A
RU2019112526A RU2019112526A RU2019112526A RU2019112526A RU 2019112526 A RU2019112526 A RU 2019112526A RU 2019112526 A RU2019112526 A RU 2019112526A RU 2019112526 A RU2019112526 A RU 2019112526A RU 2019112526 A RU2019112526 A RU 2019112526A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
combinations
solvent
acid
Prior art date
Application number
RU2019112526A
Other languages
Russian (ru)
Other versions
RU2741801C2 (en
RU2019112526A3 (en
Inventor
Мария Николаевна Кондрашова
Елена Геннадьевна Литвинова
Марина Владимировна Акуленко
Мария Николаевна Тутукина
Армен Алексанович Овсепян
Original Assignee
Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН) filed Critical Федеральное государственное бюджетное учреждение науки Институт теоретической и экспериментальной биофизики Российской академии наук (ИТЭБ РАН)
Priority to RU2019112526A priority Critical patent/RU2741801C2/en
Publication of RU2019112526A publication Critical patent/RU2019112526A/en
Publication of RU2019112526A3 publication Critical patent/RU2019112526A3/ru
Application granted granted Critical
Publication of RU2741801C2 publication Critical patent/RU2741801C2/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/63Arthropods
    • A61K35/64Insects, e.g. bees, wasps or fleas
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • A61P31/06Antibacterial agents for tuberculosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Insects & Arthropods (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Communicable Diseases (AREA)
  • Animal Husbandry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Claims (28)

1. Фармацевтическая композиция, обладающая антиоксидантной активностью, полученная из личинок Galleria mellonella, включающая следующие ингредиенты:1. Pharmaceutical composition with antioxidant activity, obtained from larvae of Galleria mellonella, including the following ingredients: тимоген от 0,5 до 6 мкг/мл, предпочтительно 4-5 мкг/мл;thymogen 0.5 to 6 μg / ml, preferably 4-5 μg / ml; тимозин-бета от 0,5 до 3 мкг/мл, предпочтительно 2 мкг/мл;thymosin beta 0.5 to 3 μg / ml, preferably 2 μg / ml; лизоцим от 0,1 до 2 мкг/мл, предпочтительно 1 мкг/мл;lysozyme 0.1 to 2 μg / ml, preferably 1 μg / ml; супероксиддисмутаза от 1 до 15 мкг/мл, предпочтительно 8 мкг/мл;superoxide dismutase 1 to 15 μg / ml, preferably 8 μg / ml; аспарагиновую кислоту от 100 до 800 мкг/мл, предпочтительно 500 мкг/мл;aspartic acid 100 to 800 μg / ml, preferably 500 μg / ml; глутаминовую кислоту от 200 до 1000 мкг/мл, предпочтительно 700 мкг/мл;glutamic acid 200 to 1000 μg / ml, preferably 700 μg / ml; глицин от 50 до 500 мкг/мл, предпочтительно 300 мкг/мл;glycine 50 to 500 μg / ml, preferably 300 μg / ml; аланин от 300 до 1500 мкг/мл, предпочтительно 1000 мкг/мл;alanine from 300 to 1500 μg / ml, preferably 1000 μg / ml; лимонную кислоту от 500 до 1500 мкг/мл, предпочтительно 1000 мкг/мл;citric acid from 500 to 1500 μg / ml, preferably 1000 μg / ml; изолимонную кислоту от 100 до 500 мкг/мл, предпочтительно 250 мкг/мл;isolic acid from 100 to 500 μg / ml, preferably 250 μg / ml; альфа-кетоглутаровую кислоту от 10 до 100 мкг/мл, предпочтительно 60 мкг/мл.alpha-ketoglutaric acid 10 to 100 μg / ml, preferably 60 μg / ml. 2. Фармацевтическая композиция по п. 1, характеризующаяся тем, что ее антиоксидантная активность, измеренная методом ингибирования аутоокисления адреналина, составляет от 20 до 500 ед./мл, преимущественно 200 ед/мл.2. A pharmaceutical composition according to claim 1, characterized in that its antioxidant activity, measured by the method of inhibition of adrenaline autooxidation, is from 20 to 500 U / ml, preferably 200 U / ml. 3. Фармацевтическая композиция по п. 1, характеризующаяся тем, что ее антиоксидантная активность, измеренная методом ингибирования люминесценции, сопровождающей термическое разложение α,α'-азодиизобутироамидин дигидрохлорида, составляет от 100 до 1200 ед./мл, преимущественно 500 ед./мл.3. The pharmaceutical composition according to claim 1, characterized in that its antioxidant activity, measured by the method of inhibition of luminescence accompanying thermal decomposition of α, α'-azodiisobutyroamidine dihydrochloride, is from 100 to 1200 U / ml, preferably 500 U / ml. 4. Фармацевтическая композиция по пп. 1-3, обладающая нормализующим состояние симпатической гиперактивности свойством.4. The pharmaceutical composition according to PP. 1-3, which has a property normalizing the state of sympathetic hyperactivity. 5. Фармацевтическая композиция по п. 1, проявляющая лечебное действие при остром стрессе, ишемии миокарда, туберкулезе, а также стимулирующая заживление инфицированных ран.5. The pharmaceutical composition according to claim 1, exhibiting a therapeutic effect in acute stress, myocardial ischemia, tuberculosis, and also stimulates the healing of infected wounds. 6. Фармацевтическая композиция по п. 1, характеризующаяся тем, что диапазон ее дозировок составляет, в мг сухого веществ на кг массы тела в сутки, для мыши 7,5-135; для крысы 5-90; для человека от 1 до 20 мг сухого вещества/кг массы тела в сутки.6. The pharmaceutical composition according to claim 1, characterized in that the range of its dosages is, in mg of dry matter per kg of body weight per day, for a mouse 7.5-135; for rats 5-90; for a person from 1 to 20 mg dry matter / kg body weight per day. 7. Фармацевтическая композиция по п. 1, в форме раствора, в форме сухой смеси, порошка или таблетки, капсулы или пастилки.7. A pharmaceutical composition according to claim 1, in the form of a solution, in the form of a dry mix, powder or tablet, capsule or lozenge. 8. Фармацевтическая композиция по п. 7, представляющая собой раствор, который дополнительно содержит стабилизаторы и/или консерванты, и/или целевые добавки, и/или их комбинации.8. A pharmaceutical composition according to claim 7, which is a solution that additionally contains stabilizers and / or preservatives and / or targeted additives and / or combinations thereof. 9. Фармацевтическая композиция по п. 8, в которой целевые добавки представляют собой экстракты лекарственных растений.9. A pharmaceutical composition according to claim 8, wherein the targeted additives are herbal extracts. 10. Фармацевтическая композиция по п. 7, представляющая собой таблетку или капсулу, или пастилку, которая дополнительно содержит вспомогательные вещества и/или целевые добавки, и/или их комбинации.10. A pharmaceutical composition according to claim 7, which is a tablet or capsule or lozenge, which additionally contains auxiliary substances and / or targeted additives, and / or their combinations. 11. Фармацевтическая композиция по п. 10, в которой вспомогательные вещества выбраны из группы, включающей стеарат кальция, микрокристаллическую целлюлозу, сорбит, сахаристую массу, диоксид кремния, желатин, жир, липосомы, глицерин, коллидон, диетическую клетчатку и их комбинации.11. The pharmaceutical composition according to claim 10, in which the excipients are selected from the group consisting of calcium stearate, microcrystalline cellulose, sorbitol, sugar mass, silicon dioxide, gelatin, fat, liposomes, glycerin, collidone, dietary fiber, and combinations thereof. 12. Фармацевтическая композиция по п. 10, в которой целевые добавки выбраны из группы, включающей ароматизаторы, пищевые консерванты, пищевые антиоксиданты, красители, вкусовые вещества, эссенции, витамины, премиксы, органические кислоты, экстракты лекарственных растений и их комбинации.12. The pharmaceutical composition according to claim 10, in which the targeted additives are selected from the group consisting of flavorings, food preservatives, food antioxidants, colorants, flavors, essences, vitamins, premixes, organic acids, herbal extracts and combinations thereof. 13. Способ получения фармацевтической композиции по п. 1, включающий выращивание личинок Galleria mellonella с использованием смеси темной восковой суши и мервы или перговой крошки в качестве кормовой смеси, их лиофилизацию или замораживание и экстракцию из них композиции растворителем.13. A method of obtaining a pharmaceutical composition according to claim 1, comprising growing the larvae of Galleria mellonella using a mixture of dark wax sushi and merv or pearl crumbs as a feed mixture, lyophilizing or freezing them and extracting the composition from them with a solvent. 14. Способ по п. 13, в котором кормовая смесь дополнительно содержит сахарный сироп.14. The method of claim 13, wherein the feed mixture further comprises sugar syrup. 15. Способ по п. 13, в котором растворитель выбран из группы, включающей спиртовой раствор, физиологический раствор, воду, глицерин и их комбинации.15. The method of claim 13, wherein the solvent is selected from the group consisting of an alcohol solution, saline, water, glycerin, and combinations thereof. 16. Способ, по п. 13, в котором в экстрагирующий растворитель добавлен дигидрокверцетин.16. The method of claim 13, wherein dihydroquercetin is added to the extraction solvent. 17. Способ по п. 13, в котором экстракцию композиции проводят дважды, при этом повторную экстракцию осуществляют частью первоначального объема растворителя.17. The method of claim 13, wherein the composition is extracted twice, with re-extraction being performed with a portion of the original volume of solvent.
RU2019112526A 2019-04-24 2019-04-24 Pharmaceutical composition from galleria mellonella larvae and a method for production thereof RU2741801C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2019112526A RU2741801C2 (en) 2019-04-24 2019-04-24 Pharmaceutical composition from galleria mellonella larvae and a method for production thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2019112526A RU2741801C2 (en) 2019-04-24 2019-04-24 Pharmaceutical composition from galleria mellonella larvae and a method for production thereof

Publications (3)

Publication Number Publication Date
RU2019112526A true RU2019112526A (en) 2020-10-26
RU2019112526A3 RU2019112526A3 (en) 2020-10-26
RU2741801C2 RU2741801C2 (en) 2021-01-28

Family

ID=72944335

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019112526A RU2741801C2 (en) 2019-04-24 2019-04-24 Pharmaceutical composition from galleria mellonella larvae and a method for production thereof

Country Status (1)

Country Link
RU (1) RU2741801C2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113662971B (en) * 2021-08-30 2023-02-24 江西省养蜂研究所(江西省蜂业技术推广站) Natural bee bread buccal tablet and production method thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2038086C1 (en) * 1991-03-26 1995-06-27 Спиридонов Николай Алексеевич Method for extracting biologically active product from wax moth larvae
RU2280463C1 (en) * 2005-03-28 2006-07-27 Федеральное государственное образовательное учреждение высшего профессионального образования Ставропольский государственный аграрный университет Method for producing preparation increasing organism resistance
MD4198C1 (en) * 2011-08-26 2013-09-30 Вячеслав ЧУХРИЙ Complex of entomological origin in propylene glycol with keratolytic action, process for its preparation, pharmaceutical and cosmetic products based on it (embodiments)
UA68907U (en) * 2011-11-16 2012-04-10 Анатолий Романович Трачук Dietetic additive based on alcoholic extract of larvas of greater wax moth galleria mellonella

Also Published As

Publication number Publication date
RU2741801C2 (en) 2021-01-28
RU2019112526A3 (en) 2020-10-26

Similar Documents

Publication Publication Date Title
Amit et al. Phytosome: Phytolipid drug delivery system for improving bioavailability of herbal drug
US8084061B2 (en) Body fat-reducing agent
KR101856602B1 (en) Composition comprising the extracts of teleogryllus emma as an effective component for antioxidation
KR101898688B1 (en) Composition for preventing, treating or improving muscle atrophy comprising complex extracts
KR20170078504A (en) Composition comprising extract of Hydrangeae Dulcis Folium for preventing and treating of stress diseases
KR101989407B1 (en) A composition for promoting melanin synthesis comprising Cirsium japonicum extract
KR101088069B1 (en) Novel use of Panduratin derivatives or extract of Kaempferia pandurata comprising the same
KR20100084447A (en) Bee extract for anti-inflammation
RU2019112526A (en) Pharmaceutical composition of Galleria mellonella larvae and method for its production
WO2020052571A1 (en) Use of combretum micranthum extract in cosmetics
KR101821925B1 (en) A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis
WO2022169066A1 (en) Functional collagen composition using aurea helianthus-derived collagen amino acid
WO2008069604A1 (en) Composition comprising the mixed herbal extract of aralia cordata thunb. and cimicifuga heracleifolia kom. for preventing and treating inflammatory disease and pain disease
KR101738206B1 (en) A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis
KR20080088163A (en) Pharmaceutical composition comprising the fractions of root of polygonum cuspidatum for neuroprotective effect
KR102395338B1 (en) Oral composition for improving systemic symptoms including sensitivity to cold
KR101017734B1 (en) A composition comprising the dried powder of Squid fraction or the extract thereof for preventing and treating hyperlipidemia
KR102401597B1 (en) Protectant against neuronal cell death by oxidative stress comprising l-serine and the root extract of angelica gigas as an effective component
KR100885073B1 (en) Pharmaceutical composition comprising the extracts of root of Polygonum cuspidatum for neuroprotective effect
KR100901188B1 (en) Composition containing hydrolysates of mackerel pike for prevention or attenuation of cognitive impairment
KR101546752B1 (en) The glycan polymer derived from e.terrestris larvae induced production of nitrix oxide, having repeating unit of zylitol derivatives
WO2021249960A1 (en) Compositions comprising narcissus spp. plant extract and use thereof
KR20230111743A (en) Pharmaceutical composition comprising the extract of Rhamnella frangulioides (Maxim.) Weberb. for immunomodulation
KR101048265B1 (en) Composition for preventing and treating hyperlipidemia comprising salmon fraction dry powder or extract thereof as an active ingredient
KR101505870B1 (en) Composition for improving or treating memory loss due to degenerative dementia and preparation method thereof